INTRODUCTION
Rheumatoid arthritis (RA) is a complex disease, and so far numerous genetic susceptibility loci have been identified and established by both candidate gene and genome-wide association studies. [1] [2] [3] [4] [5] However, the genetic variants confirmed so far as risk factors for RA only explain a small proportion of the underlying genetic risk contribution for disease development. 6, 7 In the last decade, there has been a marked increase in our understanding and knowledge regarding the genome content and the architecture of structural variants. [8] [9] [10] [11] Although the total genomic copy number variation (CNV) content has been shown to be smaller than initial findings suggested, 11 CNV variation comprises a larger fraction of the genome compared with singlenucleotide polymorphisms, 12 and has been shown to have important phenotypic effects on gene expression. 13, 14 Hence, structural variations, including CNVs, have been suggested to contribute to the susceptibility to complex diseases, such as RA. Several whole-genome surveys of CNVs have been conducted, but whole-genome CNV studies of complex diseases have been limited. 15 The Wellcome Trust Case-Control Consortium CNV genome-wide association studies concluded that common structural variation explains only a small proportion of the underlying genetic risk of RA. 15 However, rare and/or complex CNVs could still contribute to the overall genetic risk and therefore candidate studies of CNVs are important complements for genome-wide association studies.
One such complex CNV is the copy variable gene C-C chemokine ligand 3-like 1 (CCL3L1), which encodes the macrophage inflammatory protein-1a that is known to bind to the chemokine receptor 5 (CCR5) expressed by both CD4 þ and CD8 þ T cells present in the inflamed synovium of RA patients. Chemokines, a family of small chemotactic cytokine-like molecules, have the ability to recruit leukocytes into the joints, and further activate them through the interaction with chemokine receptors present on the leukocyte surface. Elevated levels of chemokines in the inflamed synovium indicate that a chemokinereceptor-mediated immune response is important in RA. 16 The CCR5 receptor has immunologically important features, as animal models of RA have shown to be partially blocked by CCR5 antagonists or anti-CCR5 antibodies, 17, 18 but the genetic evidence for CCR5 involvement in RA has been inconsistent. 19, 20 RA patients can be classified into two major subsets, anticitrullinated peptide antibodies (ACPA)-positive and ACPA-negative. Although the clinical phenotype of these two groups of patients is similar in early phase of the disease, the ACPA-positive patients develop a more aggressive and severe disease. 21 In line with increased disease activity, investigation of synovial tissue samples has shown a higher mean number of infiltrating lymphocytes in the ACPA-positive compared with the ACPAnegative patients. 22 The elevated number lymphocytes in ACPApositive could potentially be mediated by an elevated level of chemotactic macrophage inflammatory protein-1a in the inflamed synovium of these patients. Genetically, RA patients positive for ACPA have shown to differ from ACPA-negative patients, 5, 23 indicating different biological mechanisms. 1 The CCL3L1 locus is located in a chemokine dense cluster on the long arm of chromosome 17. Within this region there is B90-kb repeat unit including the copy number variable chemokine genes CCL3L1 and CCL4L1, among others. These chemokine genes show a high degree of structural and functional similarity that argues for multiple duplication events through evolution. Variation in copy number of CCL3L1 has previously been investigated with susceptibility to RA 15, 24, 25 and other complex diseases. 26, 27 The investigations of the genetic contribution of CCL3L1 to RA have been done by three different genotyping methods, comparative genomic hybridization, quantitative (q) PCR and paralogue ratio test (PRT). 15, 24, 25 One of these studies reported an association with higher than the average copy number of CCL3L1 (2 ¼ average), 24 whereas the two other studies 15, 25 could not confirm this finding. In particular, the well-powered CNV genome-wide association study conducted by the Wellcome Trust Case-Control Consortium, compared about 2000 RA patients and 3000 controls, found no significant association with CCL3L1. 15 Importantly, none of the previous studies have stratified their patients according to ACPA status, which could have hampered the detection of a true association. Lack of replication could therefore be caused by several factors such as inadequate power 25 or population or clinical heterogeneity, 28 or in fact be attributable to the vulnerability to error of CNV genotyping per se. 15, 25, 27, 29 Given the inconsistent results regarding CCL3L1 involvement in RA, replication in independent cohorts of patients is necessary, particularly taking ACPA status into account. We have adopted the modified PRT method for genotyping of the CCL3L1 locus 25 and performed association testing in independent Norwegian RA case-control material. Several studies have shown that the PRT method developed for the CCL3L1 locus is an accurate and robust genotyping method where confident allocation of samples to specific integer copy numbers is possible in the majority of cases. 25, 27, 30 RESULTS AND DISCUSSION The distribution of the raw ratio data generated by the three PRT systems demonstrated a good correlation between the three individual measures, with clearly defined clusters representing 0, 1, 2, 3 and 4 or more copies for both RA patients and controls ( Supplementary Figures 1 and 2) . The high level of concordance observed between the three systems in our data set suggests that the copy numbers of CCL3L1 and CCL4L1 within an individual are identical.
Careful investigation of our data provided evidence for differential bias as the maxima in the clusters for the raw data and the integer copy number data did not center on the same value for cases and controls (Supplementary Figure 1) . Further, detailed analysis showed that the differential bias was predominantly caused by the CCL3C PRT system within the patients' data set. The magnitude of this shift appeared to be about 10% of the integer value, or about 0.2 repeats for two copy samples. The differential bias was seen for all copy numbers, and a kernel density plot illustrates the differential bias for the full data set (Supplementary Figure 3) ; however, for the vast majority of samples (96%) the integer copy number distribution was unchanged as the differential bias was proportionally slight. Several causes are possible for the differential bias observed. Previous studies have shown that differential bias is introduced by different DNA extraction methods and source of DNA for samples. 15, 25 This is not a probable cause for our material, as peripheral blood mononuclear cells were extracted from both patients and controls by the same method. However, a more probable cause could be dissimilar purity of the samples caused by different storage regimes; the control DNAs were extracted B5 years ago, whereas the patient DNAs were extracted B10 years ago and hence may have undergone more freeze/thaw cycles that could potentially degrade DNA and affect the CNV typing. Before investigation for bias in the data set, initial association analysis by t-test falsely suggested a significant association; P ¼ 6.29 Â 10 À 11 for analysis of the unrounded mean copy number data and P ¼ 0.07 for analysis with integer copy numbers. This emphasizes the need for careful analysis of detailed genotype data before any conclusions can be drawn.
To meet these challenges of differential bias, we implemented the CNVtools package especially designed for CNV data, 31 to assign integer copy number and simultaneously test for association in the data set. This package has the further advantage that it can control for differential bias between the case and control data set. As calibration of the samples by the reference samples was inadequate (see Supplementary Text), the mean ratio data generated from the three PRT systems was used as input. Before formal association analysis the mixture model was altered to identify the parameters that best fitted our data. Complete convergence of the data was achieved using a linear model, the Gaussian distribution (Supplementary Figure 4) , six component classes, 3000 iterations and after controlling for batch effects of the mean and the variance. The posterior probability of assignment to each of the six component classes was calculated for all samples in the study under the null hypothesis of no association (H0) and under the alternative hypothesis of association (H1). The posterior probabilities generated for each sample under both H0 and H1 hypothesis were very similar and assigned integer copy numbers ranging between 0 and 5 for the full data set (see Table 1 ). The formal test of association in CNVtools is a Abbreviations: ACPA, anti-citrullinated peptide antibody; PRT, paralogue ratio test; RA, rheumatoid arthritis. Genomic DNA for 905 ACR 37 classified RA patients and 905 healthy controls were genotyped on separate 96-well plates for the CNV, CCL3L1, by the previously described PRT method. 25 Only one modification to the PRT protocol was introduced by changing from FAM to VIC labeling of the CCL3L1/CCL3 forward primer. Fluorescently labeled amplification products were separated on an ABI3730 instrument followed by inspection of electropherograms by GeneMapper v3.7 (ABI, Foster City, CA, USA). Ratios for each of the three PRT assays were calculated separately by calculating the ratio of test to reference peak area. Reference samples with established copy number from the cell lines A431, OVCAR-5, NA12044 and NA10859 were included on genotyped plates (see Supplementary Text for complementary information regarding reference samples).
likelihood ratio test from a comparison of the log-likelihoods generated under H0 and H1 hypotheses. Association analysis was performed between the Norwegian controls with all the RA cases together and also separately with ACPA-positive and ACPAnegative cases, as well as analysis comparing the ACPA-positive and ACPA-negative cases. The likelihood ratios are presented for all analyses in Table 2 , and no significant difference was observed for any of the tests.
Our finding, of no association between CCL3L1 copy number and susceptibility to RA, is consistent with findings in three previous RA case-control studies in the United kingdom, 15, 24, 25 but in contrast to a RA case-control study from New Zealand. 24 The latter study claimed that their observation of genetic interaction between CCR5 and CCL3L1 supported the validity of their association between RA and CCL3L1 CN42.
Limited power and clinical or population heterogeneity 28 between the studies can potentially explain the conflicting results. Given odds ratio ¼ 1.3 and a probability of exposure among controls of 28%, based on findings in the New Zealand study, our study had 73 and 60% power to reject the H0 at a ¼ 0.05, for all RA and ACPA-positive patients, respectively. Technical challenges within the different CNV genotyping methods (qPCR, PRT and comparative genomic hybridization) could be another reason for the inconsistent results. Genotyping of the CCL3L1 locus by both qPCR and PRT, in a recent type 1 diabetes study, 27 showed, in line with reports for other CNV loci, 32, 33 a displacement of copy number distribution toward higher copy numbers after qPCR compared with PRT. Simultaneous amplification of test and reference loci under the same PCR conditions in PRT decreases the experimental variability compared with qPCR, where distinct test and reference amplicons are amplified. The technical difficulties in current genotyping assays available for CCL3L1 detection have been highly debated and illustrate the challenges in multiallelic CNV genotyping in general. 27, 29, [34] [35] [36] Genotyping of a large Norwegian RA case-control sample by PRT produced data that clearly defined clusters representing zero to five copies of CCL3L1. We show the importance of careful inspection of raw genotyping data and the application of the package CNVtools with PRT data providing a robust statistical framework for association analysis. In conclusion, our findings neither support involvement of the CCL3L1/CCL4L1 CNV region in RA, nor in either of the ACPA subgroups. 31 This package performs robust case-control association analysis of CNVs by simultaneously assigning posterior probabilities of integer copy number for each sample from the unrounded copy number estimates and implementing a likelihood ratio test. Before the association analysis, the best-fit mixture model for the unrounded data has to be found through systematic refinement of the model parameters, which include number of fitted component classes, type of modeling (free, linear and constant) for the mean and variances, incorporation of case-control batch effects and the maximum number of iterations of the fitting algorithm. Values presented are À 2(lnL[H0] À lnL[H1]), which follow a w 2 distribution with one degree of freedom, with the corresponding P-value in brackets.
